These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 2935249)
1. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249 [TBL] [Abstract][Full Text] [Related]
2. Metabolism and disposition of menogaril (NSC 269148) in the rabbit. Dodion P; Egorin MJ; Engisch KL; Bachur NR Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217 [TBL] [Abstract][Full Text] [Related]
3. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359 [TBL] [Abstract][Full Text] [Related]
4. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Ratain MJ; Schilsky RL Cancer Res; 1986 Sep; 46(9):4874. PubMed ID: 2942243 [No Abstract] [Full Text] [Related]
5. The disposition of the new anthracycline antibiotic, menogarol, in mice. Dodion P; Chang BK; Egorin MJ; Olman EA; Engisch KL; Bachur NR Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962 [TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729 [TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. Long HJ; Powis G; Schutt AJ; Moertel CG Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors. Zanette ML; Tirelli U; Sorio R; Zadro D; Figoli F; Monfardini S; D'Incalci M Cancer Chemother Pharmacol; 1987; 20(1):67-70. PubMed ID: 2957106 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244 [TBL] [Abstract][Full Text] [Related]
11. A phase I study of menogaril in patients with advanced cancer. Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065 [TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites. Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. Foster BJ; Wiegand RA; LoRusso PM; Baker LH Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052 [TBL] [Abstract][Full Text] [Related]
14. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo. Adams EG; Bhuyan BK Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401 [TBL] [Abstract][Full Text] [Related]
15. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia. McGovren JP Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690 [TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of oxaliplatin: a critical review. Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943 [TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391 [TBL] [Abstract][Full Text] [Related]
20. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]